Gemtesa (Vibegron)
vibegron tablets
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Overactive bladder (OAB) — urge urinary incontinence, urgency, urinary frequency | Adults | Monotherapy | FDA Approved |
| OAB in males with benign prostatic hyperplasia (BPH) — urge urinary incontinence, urgency, urinary frequency in males on pharmacological BPH therapy | Adult males on BPH pharmacotherapy | Monotherapy (add-on to BPH medication) | FDA Approved |
Vibegron is a selective beta-3 adrenergic receptor agonist approved by the FDA in December 2020 for overactive bladder in adults. In December 2024, it received an additional indication for OAB in adult males concurrently receiving pharmacological therapy for benign prostatic hyperplasia, supported by the phase 3 COURAGE trial. Vibegron is the second beta-3 agonist to reach market after mirabegron, but it is distinguished by the absence of CYP2D6 inhibitory activity, no blood pressure warning in the label, a fixed-dose regimen requiring no titration, and the ability to crush the tablet for patients with swallowing difficulty. The pivotal EMPOWUR trial (Study 3003) enrolled over 1,500 patients and demonstrated statistically significant reductions in micturition frequency, urge urinary incontinence episodes, and urgency episodes compared with placebo at 12 weeks.
Neurogenic detrusor overactivity in adults: Limited data exist for vibegron use in adult NDO. Based on its beta-3 agonist mechanism, off-label use may be considered when antimuscarinics and mirabegron are not tolerated. Evidence quality: Low.
Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| OAB — treatment-naive adult | 75 mg once daily | 75 mg once daily | 75 mg/day | No dose titration required Swallow whole with water, or crush and mix with ~15 mL applesauce; take with or without food |
| OAB in male with concurrent BPH pharmacotherapy | 75 mg once daily | 75 mg once daily | 75 mg/day | Same dose; add to existing BPH medication (alpha-blocker, 5-ARI, or combination) COURAGE trial demonstrated efficacy in this population |
| OAB — mild to severe renal impairment (eGFR 15–89) | 75 mg once daily | 75 mg once daily | 75 mg/day | No dose adjustment required Not recommended in ESRD (eGFR <15 with or without hemodialysis) |
| OAB — mild to moderate hepatic impairment (Child-Pugh A/B) | 75 mg once daily | 75 mg once daily | 75 mg/day | No dose adjustment required Not studied in severe hepatic impairment (Child-Pugh C); not recommended |
| OAB — elderly (≥65 years) | 75 mg once daily | 75 mg once daily | 75 mg/day | No dose adjustment; 46% of trial patients were ≥65 years with no difference in safety or efficacy Can be crushed for patients with swallowing difficulty |
Vibegron offers several practical advantages over mirabegron in specific clinical scenarios. It requires no dose titration (a single 75 mg fixed dose), has no CYP2D6 inhibitory activity (eliminating concern for interactions with metoprolol, flecainide, or tamoxifen), carries no blood pressure warning in the FDA label, and can be crushed and mixed with applesauce for patients who cannot swallow tablets. These characteristics make it particularly suitable for elderly patients on multiple medications and those with dysphagia.
Pharmacology
Mechanism of Action
Vibegron is a selective agonist of the human beta-3 adrenergic receptor. Like mirabegron, vibegron relaxes detrusor smooth muscle during the bladder filling phase by activating beta-3 receptors, thereby increasing functional bladder capacity and reducing the sensation of urgency. Vibegron demonstrates high selectivity for the beta-3 receptor subtype relative to beta-1 and beta-2 adrenergic receptors. Unlike mirabegron, vibegron does not inhibit CYP2D6, which translates into a cleaner drug interaction profile. In a dedicated ambulatory blood pressure monitoring study, vibegron 75 mg was not associated with clinically significant blood pressure changes in OAB patients, and the drug does not prolong the QT interval at a dose 5.3 times the approved recommended dose.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Tmax 1–3 h; Cmax and AUC increase greater than dose-proportionally up to 600 mg; no clinically significant food effect; can be crushed with applesauce without affecting PK | Rapid absorption; fixed 75 mg dose is effective without titration; flexibility in administration route supports patients with dysphagia |
| Distribution | Apparent Vd 6304 L; ~50% plasma protein-bound; blood-to-plasma ratio 0.9 | Very large volume of distribution indicates extensive tissue distribution; moderate protein binding makes displacement interactions unlikely |
| Metabolism | Metabolism plays a minor role in elimination; CYP3A4 is the predominant enzyme in vitro; does not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4; does not induce CYP1A2, 2B6, or 3A4; P-gp substrate but does not inhibit P-gp or other transporters | Clean interaction profile: no CYP2D6 inhibition (key difference from mirabegron); unlikely to cause clinically significant PK interactions with most co-administered drugs |
| Elimination | Effective t½ 30.8 h; 59% feces (54% unchanged), 20% urine (19% unchanged); steady state in ~7 days; accumulation ratio 1.7 (Cmax) and 2.4 (AUC0-24) | Primarily excreted as unchanged drug in feces, suggesting biliary/intestinal secretion is the dominant elimination pathway; half-life supports once-daily dosing |
Side Effects
| Adverse Effect | Incidence (Vibegron) | Placebo | Clinical Note |
|---|---|---|---|
| Headache | 4.0% | 2.4% | Most common adverse reaction; usually mild to moderate |
| Nasopharyngitis | 2.8% | 1.7% | Common in clinical trials; not clearly drug-related |
| Diarrhea | 2.2% | 1.1% | Usually self-limiting |
| Nausea | 2.2% | 1.1% | Usually mild; taking with food may help |
| Upper respiratory tract infection | 2.0% | 0.7% | Not clearly drug-related |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dry mouth | <2% | Notably lower than antimuscarinic agents; not dose-related since only one dose studied |
| Constipation | <2% | Much lower than rates seen with antimuscarinics; reported at >2% in long-term extension only |
| Residual urine volume increased | <2% | Monitor in patients with BOO or concurrent antimuscarinic use |
| Urinary retention | <2% | Risk higher with concurrent antimuscarinics or BOO |
| Hot flush | <2% | Beta-adrenergic class effect |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Urinary tract infection (52-week extension) | 6.6% | Emerged with longer treatment duration; not reported at ≥2% in the 12-week study |
| Bronchitis (52-week extension) | 2.9% | Reported in long-term use; unclear causal relationship |
| Hypertension (BPH study, 24 weeks) | 9.0% vs 8.3% placebo | Broadly defined in COURAGE trial; rates comparable to placebo; the dedicated ABPM study showed no significant BP effect at 75 mg |
| UTI (BPH study, 24 weeks) | 2.5% vs 2.2% placebo | Similar rates to placebo in male BPH population |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Angioedema | Rare (postmarketing) | Hours after first dose or after multiple doses | Immediately discontinue; provide emergency airway management; permanent discontinuation required; contraindication added to label Oct 2024 |
| Urinary retention | Rare (postmarketing) | Variable; higher risk with BOO or concurrent antimuscarinic use | Discontinue vibegron; catheterisation may be needed; listed as a warning and precaution in the FDA label |
| Hypersensitivity reactions (urticaria, pruritus, rash, drug eruption) | Rare (postmarketing) | Variable | Discontinue if significant; provide appropriate treatment |
Vibegron is the only beta-3 agonist without a blood pressure warning in its FDA label. In the dedicated ambulatory blood pressure monitoring study (n=200 OAB patients), 75 mg daily vibegron was not associated with clinically significant blood pressure changes. In the EMPOWUR trial, rates of hypertension with vibegron (1.7%) were identical to placebo (1.7%), while the tolterodine comparator arm reported a 1.7% rate. This blood pressure neutrality is a significant clinical differentiator from mirabegron, which carries a specific blood pressure monitoring requirement.
Drug Interactions
Vibegron has a notably clean drug interaction profile. It does not inhibit or induce any CYP enzymes (including CYP2D6) or major drug transporters at clinically relevant concentrations. The only clinically meaningful interaction identified in the FDA label is with digoxin. Vibegron is a CYP3A4 substrate and a P-gp substrate, but co-administration with ketoconazole (strong CYP3A4 and P-gp inhibitor), diltiazem (moderate CYP3A4 inhibitor), or rifampicin (strong CYP3A4 inducer) did not produce clinically significant changes in vibegron exposure.
Monitoring
- Digoxin LevelsBefore initiation; during therapy; after discontinuation
Trigger-basedVibegron increases digoxin Cmax 21% and AUC 11%; measure serum digoxin before starting, monitor during treatment, and continue monitoring after vibegron is stopped to guide dose adjustment - Symptom Response4–12 weeks; then every 6–12 months
RoutineAssess OAB symptoms using voiding diary or validated questionnaire; no dose titration available (fixed 75 mg dose); periodically reassess continued need for therapy - Post-Void ResidualBaseline if BOO suspected; as needed
Trigger-basedMonitor in patients with BOO or concurrent antimuscarinic medications; discontinue vibegron if urinary retention develops - Renal FunctionBaseline
RoutineAssess eGFR before initiation; no dose adjustment for eGFR 15–89; not recommended in ESRD (eGFR <15 or dialysis) - Hepatic FunctionBaseline
RoutineNo adjustment for Child-Pugh A/B; not studied and not recommended in Child-Pugh C
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity: Hypersensitivity to vibegron or any component of the formulation; includes patients with prior angioedema with vibegron (contraindication updated October 2024)
Relative Contraindications (Specialist Input Recommended)
- End-stage renal disease (eGFR <15, with or without hemodialysis): Not studied; not recommended by the FDA label
- Severe hepatic impairment (Child-Pugh C): Not studied; not recommended by the FDA label
Use with Caution
- Bladder outlet obstruction: Urinary retention has been reported; monitor PVR and symptoms of retention
- Concurrent antimuscarinic OAB medications: Increased risk of urinary retention with pharmacodynamic combination; monitor closely; discontinue vibegron if retention develops
- Patients taking digoxin: Modest increase in digoxin exposure (Cmax +21%, AUC +11%); measure digoxin levels before and during treatment
In October 2024, the FDA updated the Gemtesa label to include a warning for angioedema (section 5.2) and added hypersensitivity reactions, including angioedema, to the contraindications (section 4). Angioedema of the face and/or larynx has been reported in postmarketing experience, occurring hours after the first dose or after multiple doses. Angioedema associated with upper airway swelling may be life-threatening. Clinicians should immediately discontinue vibegron if tongue, hypopharynx, or larynx involvement occurs and provide appropriate airway management.
Patient Counselling
Purpose of Therapy
Vibegron helps manage overactive bladder symptoms by activating receptors that relax the bladder muscle during filling, allowing the bladder to hold more urine. This reduces the urgent need to urinate, the frequency of bathroom visits, and accidental leakage episodes. It works differently from older anticholinergic bladder medications and does not cause the dry mouth or constipation commonly seen with those drugs.
How to Take
Take one 75 mg tablet once daily with a glass of water. The tablet can be taken with or without food, at the same time each day. If you have difficulty swallowing, the tablet can be crushed and mixed with approximately one tablespoon (15 mL) of applesauce, then taken immediately with a glass of water. If a dose is missed and more than 12 hours have passed, skip the missed dose and take the next one at the regular time.
Sources
- Gemtesa (vibegron) tablets — Full Prescribing Information. Sumitomo Pharma America, Inc. Revised February 2025. Gemtesa PICurrent regulatory source including Dec 2024 BPH indication, Oct 2024 angioedema warning, adverse reaction Tables 1–2, PK data, and digoxin interaction.
- Gemtesa (vibegron) tablets — Original FDA Approval Label (December 2020). FDA LabelOriginal FDA-approved label for adult OAB; source for Study 3003 adverse reaction data and pharmacokinetic parameters.
- Gemtesa — DailyMed label. National Library of Medicine. DailyMedNLM-hosted label confirming fixed 75 mg dosing, renal/hepatic recommendations, and drug interaction guidance.
- Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316–324. PubMed: 32068483Pivotal phase III trial (Study 3003) in 1,515 OAB patients demonstrating vibegron 75 mg superiority over placebo for micturition frequency, UUI episodes, and urgency at 12 weeks.
- Staskin D, Varano S, Frankel J, Shortino D, Jankowich R, Mudd PN Jr. Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the phase 3 EMPOWUR trial. J Urol. 2021;205(5):1421–1429. PubMed: 3335647940-week extension of EMPOWUR confirming sustained efficacy and tolerability of vibegron 75 mg over 52 weeks; 85.7% completion rate in vibegron continuers.
- Staskin D, Owens-Grillo J, Thomas E, Rovner E, Cline K, Mujais S. Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase 3 randomized controlled COURAGE trial. J Urol. 2024;212(2):256–266. PubMed: 38717901Phase 3 COURAGE trial (Study 3005) supporting the Dec 2024 BPH indication; demonstrated vibegron efficacy in males with OAB symptoms on BPH pharmacotherapy.
- Yoshida M, Takeda M, Gotoh M, et al. Vibegron, a novel potent and selective beta-3 adrenoceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018;73(5):783–790. PubMed: 29217216Japanese phase 3 trial confirming vibegron 50 mg and 100 mg efficacy in Asian OAB patients; the 75 mg dose subsequently selected for the global programme.
- Lightner DJ, Gomelsky A, Souter L, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558–563. PubMed: 31039103AUA/SUFU guideline positioning oral pharmacotherapy (antimuscarinics and beta-3 agonists) as second-line treatment for OAB after behavioural interventions.
- American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria. J Am Geriatr Soc. 2023;71(7):2052–2081. PubMed: 37139824Lists antimuscarinics as potentially inappropriate in older adults; beta-3 agonists including vibegron are not on the Beers list, supporting preferential use in elderly OAB.
- Edmondson SD, Zhu C, Kar NF, et al. Discovery of vibegron: a potent and selective beta-3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem. 2016;59(2):609–623. PubMed: 26709102Describes the medicinal chemistry optimisation of vibegron, its beta-3 receptor selectivity profile, and the preclinical pharmacology supporting clinical development.
- Mudd PN Jr, Girard F, Bhatt DL. Clinical pharmacokinetics of vibegron in healthy adult subjects. Clin Pharmacokinet. 2021;60(1):85–95. PubMed: 32557249Population PK analysis describing vibegron absorption, distribution, elimination, and the absence of clinically significant food effects or CYP-mediated interactions.
- Mudd PN Jr, Mazzei A, Engel E, et al. Pharmacokinetics and safety of vibegron in subjects with renal or hepatic impairment. Clin Pharmacol Drug Dev. 2021;10(9):1060–1070. PubMed: 33559344Renal and hepatic impairment PK study confirming no dose adjustment needed for eGFR 15–89 or Child-Pugh A/B, supporting the simplified dosing regimen.